CA-ATOMWISE
Atomwise , the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx , a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise’s second partnership with a global incubator hub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005044/en/
As part of the strategic partnership, Atomwise will work closely with the FutuRx management team, investors and incubated portfolio companies to apply its AI technology to early-stage drug discovery projects. Atomwise and FutuRx have announced their first joint venture, A2i Therapeutics, with seed funding to leverage Atomwise’s AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target. Atomwise’s AI platform, AtomNet®, can screen more than 16 billion compounds for potential hits in less than two days and has been used by researchers around the world to find hits on targets across numerous disease applications.
“FutuRx is excited to launch a new bio convergence company jointly with a world leader in AI-based drug discovery,” said Kinneret Savitzky, PhD, Chief Executive Officer of FutuRx. “Atomwise brings a legacy of collaboration and innovation in small-molecule drug discovery to our network of leading experts from multinational pharmaceutical companies and venture capital, “We are happy that our partnership with Atomwise will introduce its innovative AI platform for drug discovery to startups and emerging biotech companies in Israel.”
“The Israeli Innovation Authority leads Israel’s Bio-convergence strategy and is happy to have FutuRx once again join this effort together with its new partner Atomwise,” said Anya Eldan, VP of the Innovation Authority and Head of Startup Division. “Atomwise is at the forefront of AI-driven drug discovery, and this partnership with FutuRx will help pursue difficult disease targets and significantly boost the Israeli AI drug discovery and bio-convergence ecosystem.”
FutuRx now joins Atomwise’s growing network of investor and corporate partnerships, which today represents a collective deal value approaching $7 billion. Since its founding, Atomwise has built a strong portfolio of joint-venture companies and partnerships with emerging biotechnology, leading pharmaceutical and agrochemical companies.
In April 2020, Atomwise expanded its strategic partnership with Hansoh Pharma , a leading biopharmaceutical company in China, after successfully completing their first hit-discovery collaboration to identify hit compounds that are specific towards an intractable drug target. This announcement came on the heels of another expanded partnership earlier this year with Bayer to continue the development of two crop protection programs. As part of the strategic partnership, Atomwise is helping Bayer increase the speed and probability of discovering and developing new crop protection products through AI.
“We are excited to see Atomwise, a Leaps by Bayer portfolio company, collaborating with FutuRx on new frontiers for addressing our shared goal of curing and preventing cancer,” said Dr. Juergen Eckhardt, Head of Leaps by Bayer.
About FutuRx
FutuRx is the leading biotechnology incubator in Israel, established in 2014 by Johnson & Johnson Innovation (JJDC, Inc.), OrbiMed Israel Partners, and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc., after winning a tender of the Israeli Innovation Authority. Recently Bayer has joined FutuRx as a strategic investor through its corporate venture LEAPS. The incubator is focused on innovative, early stage therapeutic technologies, and has established 23 companies to date. For more information about FutuRx, please visit https://www.futurx.co.il .
About Atomwise
Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets across 775 collaborations spanning more than 250 partners around the world. Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com or follow @AtomwiseInc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
British Arab Commercial Bank Partners With Volante Technologies to Modernize Payments Infrastructure With PaaS22.10.2025 15:38:00 CEST | Press release
Volante’s cloud-native platform to unify BACB’s payment operations across SWIFT, CHAPS, Faster Payments, BACS, and more Volante Technologies, the global leader in Payments as a Service (PaaS), today announced a new partnership with British Arab Commercial Bank (BACB), to modernize the bank’s payment processing infrastructure and replace legacy systems with a cloud-native platform. BACB will use Volante’s PaaS solution to automate and streamline the entirety of its payments volumes across multiple payment schemes, including SWIFT MT/ISO 20022, CHAPS, Faster Payments, BACS, and internal transfers. Volante’s solution enables BACB to move beyond legacy systems and manual processes, empowering the bank to raise straight-through processing rates and continue to provide a first-class service to its customers. BACB is an international wholesale bank, with $4.4 billion in assets, who provide a range of trade solutions to clients trading in and out of developing markets, across Africa and the Mi
Qualcomm Schedules Fourth Quarter and Fiscal 2025 Earnings Release and Conference Call22.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its fourth quarter and fiscal 2025 on Wednesday, November 5, 2025, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its fourth quarter and fiscal 2025 results which will be broadcast live on November 5, 2025, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/investor-events/default.aspx. An audio replay will be available at https://investor.qualcomm.com/news-events/investor-events/default.aspx and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and internat
XPRIZE and Avanci Launch Partnership to Provide Innovators with IP and Licensing Expertise22.10.2025 15:00:00 CEST | Press release
Collaboration ensures innovators benefit from critical resources to protect and advance breakthrough solutions XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s greatest challenges, and Avanci, the independent global leader in one-stop IP licensing platforms, today announced a partnership to empower XPRIZE innovators. For more than three decades, XPRIZE competitions have ignited bold solutions that ripple far beyond the competition itself to transform industries, inspire new technologies, and build an extraordinary global ecosystem of innovators dedicated to problem solving. This partnership with Avanci ensures that XPRIZE teams and alumni have access to the expertise and resources they need to protect, scale, and amplify their impact in the real world through access to Avanci’s expertise and experience in intellectual property (IP) protection and licensing. Tailored support from Avanci will help those entrepreneurs protect their breakthro
Cyclic Materials and VACUUMSCHMELZE Expand Partnership to Recycle Rare Earth Magnet Manufacturing Waste in the U.S.22.10.2025 15:00:00 CEST | Press release
Cyclic Materials, the advanced recycling company creating a circular supply chain for rare earth elements (REEs) and other critical materials, today announced an expansion of its partnership with VACUUMSCHMELZE (VAC), a leading developer of magnetic materials and solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022335302/en/ The companies have signed a 10-year exclusive agreement for recycling 100 percent of the magnet production byproducts (i.e. swarf) that will be produced at VAC's impressive new manufacturing facility in Sumter, South Carolina scheduled to begin operations at the end of 2025. This extended partnership builds on the 2024 agreement between both companies that ensures efficient recycling of critical materials used in high-performance permanent magnets. "At Cyclic Materials, our mission is to recover critical materials from permanent magnets that can be put back into the magnet supply chain to red
HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 45.4 Million Elevance Health Members22.10.2025 14:00:00 CEST | Press release
Coverage effective across Elevance Health’s commercial, Medicare, and Medicaid plans in 14 states Decision informed by growing clinical evidence, with additional real-world and long-term safety and efficacy data now being collected across global centers HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced that Elevance Health (formerly Anthem, Inc.) has issued a positive medical policy for the use of histotripsy in the treatment of liver tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022130560/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics The policy, effective October 21, 2025, expands insurance coverage across Elevance Health’s commercial, Medicare, and Medicaid plans in 14 states, including California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virgin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom